News | August 03, 2024
Eris Lifesciences posts Q1 FY25 at Rs. 89 Cr
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development
Subscribe To Our Newsletter & Stay Updated
